Status:
TERMINATED
11C Topotecan PET Imaging
Lead Sponsor:
Case Comprehensive Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lung Cancer
Metastatic Cancer
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET scan) using 11C topotecan, may help doctors predict a patient's response to treatment and help plan the best treatment. PUR...
Detailed Description
OBJECTIVES: Primary * Determine if tumor uptake of \^11C topotecan occurs quickly enough and at sufficient concentration to be measured immediately following infusion in patients with brain metastas...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed ovarian cancer, small cell lung cancer, or other cancers
- Metastatic brain disease
- Eligible for topotecan therapy
- Measurable disease by CT scan and/or MRI
- PATIENT CHARACTERISTICS:
- Performance status
- ECOG 0-2
- Life expectancy
- More than 3 months
- Hematopoietic
- WBC ≥ 3,000/mm\^3
- Platelet count ≥ 100,000/mm\^3
- Hepatic
- Not specified
- Renal
- Creatinine clearance ≥ 50 mL/min
- Other
- Not pregnant or nursing
- Adequate end-organ function
- Able to tolerate lying on a radiology table for ≥ 1 hour
- No serious medical or psychiatric illness that would preclude study compliance or giving informed consent
- PRIOR CONCURRENT THERAPY: Not specified
Exclusion
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT00253461
Start Date
December 1 2004
End Date
November 1 2009
Last Update
March 20 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106-5065